Abstract

The work is devoted to the docking research of the mechanism of action of the nonsteroidal anti-inflammatory agent of the imidazothiazine type, 3-[(3,5-dichloropyridin-2-yl)oxy]-3,4-dihydro-2H-benzo[4,5]imidazo[2,1- b][1,3]-thiazine. The synthesized compound 4q with previously established high antioxidant activity was investigated for the docking of one molecule with another – molecular docking. According to the results of the experiment, it was established that the mechanism of anti-inflammatory activity of 4q is based on non-selective effect on cyclooxygenases of the first and second types. According to the docking simulation results, the presence of chlorine atom in the 4q molecule creates additional hydrophobic interaction that increases the total binding energy. As a result of the docking studies, it was found that 3-[(3,5-dichloropyridin-2-yl)oxy]-3,4-dihydro-2H-benzo[4,5] imidazo[2,1-b][ 1,3]-thiazine 4q when bound to COX-1 is placed in a hydrophobic pocket, the structure of which consists of a series of lipophilic amino acids, ILE563, VAL349, ALA527, LEU352, TRP387, PHE518, TYR385, TYR348, LEU 384. Additionally, 4q shows good binding to the active site of COX-2. This interaction is implemented due to hydrophobic interactions with a number of amino acids, VAL509, ALA513, VAL335, LEU370, TRP373 and TYR 371. Performed docking studies showed that 3-[(3,5-dichloropyridin-2-yl)oxy]-3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b] [1,3]-thiazine 4q forms a number of additional bonds with LEU338 (Pi-amide), ALA502 (Pi-alkyl), GLY512 (hydrogencarbon bond). However, similar to the binding to the COX-1 enzyme, the tested compound 4q did not form any hydrogen bonds. It was shown that 3-((3,5-dichloropyridin-2-yl)oxy)-3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]-thiazine 4q which demonstrated good binding to COX-1 and COX-2 enzymes in in silico docking studies even without the formation of hydrogen bonds can be used as an effective model scaffold for the design of new potential non-steroidal anti-inflammatory agents.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.